Pipeline
Atlantic Healthcare’s most advanced development programme – Camligo™ (alicaforsen enema) – is undergoing a Phase 3 trial in the treatment of orphan-designated pouchitis.
We are also progressing alicaforsen enema in ulcerative colitis and oral tablet formulations for the treatment of Crohn’s disease and ulcerative colitis.
Renzapride has wide applicability for the treatment of GI motility disorders, many of which represent significant unmet medical needs. Target indications will be disclosed in due course.
| Product | Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved |
| ALICAFORSEN | |||||
| Enema – Pouchitis |  |
||||
| Enema – UC |  |
||||
| Tablet – Crohn’s |  |
||||
| Tablet – UC | |
||||
| RENZAPRIDE | |||||
| Gut motility | |
||||
Inflammatory Bowel Disease (IBD)
Inflammatory Bowel Disease (IBD) is caused by a chronic activation of the immune system in the gastrointestinal (GI) tract.
Ulcerative colitis (UC) is an autoimmune disease where the colon (large intestine or bowel) and rectum become inflamed.
Pouchitis is a rare inflammatory disease of the pouch for which there is no approved treatment.
Crohn’s Disease is an autoimmune disease which can affect any part of the digestive system, from the mouth to the anus.